Verona Pharma PLC
VRNA104.770USD
+0.100+0.10%
Cierre 07/15, 16:00（ET）Cotizaciones retrasadas 15 min
71.35BCap. mercado
PérdidaP/E TTM
Más Datos de Verona Pharma PLC Compañía
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Información de la empresa
Símbolo de cotizaciónVRNA
Nombre de la empresaVerona Pharma PLC
Fecha de salida a bolsaMar 30, 2005
Fundada en2005
Director ejecutivoDr. David S. Zaccardelli, Pharm.D.
Número de empleados209
Tipo de seguridadDepository Receipt
Fin del año fiscalMar 30
DirecciónRiverside
CiudadLONDON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalSE1 2RE
Teléfono442032834200
Sitio Webhttps://www.veronapharma.com/
Símbolo de cotizaciónVRNA
Fecha de salida a bolsaMar 30, 2005
Fundada en2005
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
677.38K
-53.74%
Dr. David S. Zaccardelli, Pharm.D.
Dr. David S. Zaccardelli, Pharm.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
530.46K
+35.57%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
--
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
677.38K
-53.74%
Dr. David S. Zaccardelli, Pharm.D.
Dr. David S. Zaccardelli, Pharm.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
530.46K
+35.57%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
--
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 18 de may
Actualizado: dom., 18 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
7.71%
Janus Henderson Investors
6.48%
Darwin Global Management Ltd
4.61%
Frazier Life Sciences Management, L.P.
4.06%
Ali (Behbahani)
3.75%
Other
73.39%
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
7.71%
Janus Henderson Investors
6.48%
Darwin Global Management Ltd
4.61%
Frazier Life Sciences Management, L.P.
4.06%
Ali (Behbahani)
3.75%
Other
73.39%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
25.32%
Hedge Fund
23.50%
Investment Advisor
16.36%
Private Equity
12.00%
Individual Investor
10.67%
Venture Capital
5.02%
Research Firm
3.63%
Family Office
1.18%
Bank and Trust
0.26%
Other
2.06%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
405
82.30M
96.67%
-3.99M
2025Q1
406
83.91M
98.59%
+940.31K
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Perceptive Advisors LLC
6.56M
7.71%
+171.23K
+2.68%
Mar 31, 2025
Janus Henderson Investors
5.52M
6.48%
+3.85M
+230.91%
Mar 31, 2025
Darwin Global Management Ltd
3.92M
4.61%
+3.11M
+384.08%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
3.46M
4.06%
+73.90K
+2.18%
Mar 31, 2025
Ali (Behbahani)
3.19M
3.75%
+3.19M
--
Jan 16, 2025
Eventide Asset Management, LLC
2.89M
3.4%
-238.69K
-7.62%
Mar 31, 2025
RTW Investments L.P.
2.85M
3.35%
+1.03M
+56.44%
Mar 31, 2025
New Enterprise Associates (NEA)
2.69M
3.16%
-1.40M
-34.18%
Mar 31, 2025
Summit Partners Public Asset Management, LLC
2.32M
2.73%
+421.09K
+22.14%
Mar 31, 2025
Wellington Management Company, LLP
2.13M
2.5%
-893.74K
-29.54%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
ALPS Medical Breakthroughs ETF
5.89%
AdvisorShares Dorsey Wright ADR ETF
5.19%
First Trust IPOX Europe Equity Opportunities ETF
1.75%
ProShares Ultra Nasdaq Biotechnology
0.85%
First Trust International Equity Opportunities ETF
0.8%
Invesco Nasdaq Biotechnology ETF
0.72%
iShares Biotechnology ETF
0.44%
JPMorgan Healthcare Leaders ETF
0.43%
Even Herd Long Short ETF
0.32%
Goldman Sachs Innovate Equity ETF
0.16%
Ver más
ALPS Medical Breakthroughs ETF
Proporción5.89%
AdvisorShares Dorsey Wright ADR ETF
Proporción5.19%
First Trust IPOX Europe Equity Opportunities ETF
Proporción1.75%
ProShares Ultra Nasdaq Biotechnology
Proporción0.85%
First Trust International Equity Opportunities ETF
Proporción0.8%
Invesco Nasdaq Biotechnology ETF
Proporción0.72%
iShares Biotechnology ETF
Proporción0.44%
JPMorgan Healthcare Leaders ETF
Proporción0.43%
Even Herd Long Short ETF
Proporción0.32%
Goldman Sachs Innovate Equity ETF
Proporción0.16%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
